{"id":398,"date":"2026-02-19T00:46:22","date_gmt":"2026-02-18T15:46:22","guid":{"rendered":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gh\/wp\/research\/research-detail\/research-group-3\/"},"modified":"2026-02-19T00:46:22","modified_gmt":"2026-02-18T15:46:22","slug":"research-group-3","status":"publish","type":"page","link":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gh\/research\/research-detail\/research-group-3\/","title":{"rendered":"\u809d\u75be\u60a3\u81e8\u5e8a\u7814\u7a76\u30b0\u30eb\u30fc\u30d7"},"content":{"rendered":"\n\n
\n
\n\n
\n
\n

\u809d\u75be\u60a3\u81e8\u5e8a\u7814\u7a76\u30b0\u30eb\u30fc\u30d7<\/h2>\n <\/div>\n\n
\n
\n

\u30b0\u30eb\u30fc\u30d7\u30ea\u30fc\u30c0\u30fc\uff1a\u7530\u7551\u512a\u8cb4<\/h2>\n

\u30b3\u30f3\u30bb\u30d7\u30c8\uff1aReal-World Evidence \u2500 \u65e5\u5e38\u8a3a\u7642\u306e\u7591\u554f\u3092\u591a\u65bd\u8a2d\u30c7\u30fc\u30bf\u3067\u691c\u8a3c\u3057\u3001\u8a3a\u7642\u3078\u9084\u5143\u3059\u308b<\/h3>\n

\u79c1\u305f\u3061\u306f\u3001\u65e5\u5e38\u8a3a\u7642\u3067\u751f\u307e\u308c\u308b\u809d\u75be\u60a3\u306e clinical question \u3092\u51fa\u767a\u70b9\u306b\u3001\u81e8\u5e8a\u7814\u7a76\u3067\u30a8\u30d3\u30c7\u30f3\u30b9\u3078\u6607\u83ef\u3057\u3001\u305d\u306e\u6210\u679c\u3092\u8a3a\u7642\u3078\u9084\u5143\u3059\u308b\u3053\u3068\u3092\u7406\u5ff5\u3068\u3057\u3066\u3044\u307e\u3059\u3002\u5927\u962a\u5927\u5b66\u304a\u3088\u3073\u95a2\u9023\u65bd\u8a2d\u304b\u3089\u306a\u308bOsaka Liver Forum\uff08OLF\uff09\u3092\u7814\u7a76\u57fa\u76e4\u306b\u3001B\u578b\u30fbC\u578b\u809d\u708e\u3001\u8102\u80aa\u6027\u809d\u75be\u60a3\uff08MASLD\/MetALD\uff09\u30fb\u30a2\u30eb\u30b3\u30fc\u30eb\u95a2\u9023\u809d\u75be\u60a3\u3001\u809d\u786c\u5909\u3001\u809d\u7d30\u80de\u764c\u3092\u5bfe\u8c61\u3068\u3057\u3066\u3001\u9577\u671f\u8ee2\u5e30\u3001\u6cbb\u7642\u52b9\u679c\u3001\u5b89\u5168\u6027\u3001\u767a\u304c\u3093\u30ea\u30b9\u30af\u306e\u8a55\u4fa1\u3068\u5c64\u5225\u5316\u3092\u63a8\u9032\u3057\u307e\u3059\u3002\u81e8\u5e8a\u60c5\u5831\u306b\u52a0\u3048\u4fdd\u5b58\u8840\u6e05\u3001\u306a\u3089\u3073\u306b\u4e00\u90e8\u75c7\u4f8b\u306e\u809d\u7d44\u7e54\u3082\u6d3b\u7528\u3057\u3001\u75c5\u614b\u89e3\u660e\u3068\u65b0\u898f\u30d0\u30a4\u30aa\u30de\u30fc\u30ab\u30fc\u63a2\u7d22\u3092\u4e00\u4f53\u3067\u9032\u3081\u307e\u3059\u3002<\/p>\n <\/div>\n\n

\n \"\u7814\u7a76\u6982\u8981\u56f3\"\n <\/div>\n <\/div>\n\n
\n

B\u578b\u30fbC\u578b\u809d\u708e\u306b\u304a\u3051\u308b\u6297\u30a6\u30a4\u30eb\u30b9\u6cbb\u7642\u5f8c\u306e\u9577\u671f\u30a2\u30a6\u30c8\u30ab\u30e0\u3068\u809d\u767a\u304c\u3093\u30ea\u30b9\u30af\u5c64\u5225\u5316<\/h3>\n

B\u578b\u809d\u708e\u3067\u306f\u6838\u9178\u30a2\u30ca\u30ed\u30b0\u6cbb\u7642\u306b\u3088\u308a\u30a6\u30a4\u30eb\u30b9\u5236\u5fa1\u304c\u3001C\u578b\u809d\u708e\u3067\u306fDAA\u6cbb\u7642\u306b\u3088\u308a\u30a6\u30a4\u30eb\u30b9\u6392\u9664\u304c\u53ef\u80fd\u3068\u306a\u308a\u307e\u3057\u305f\u304c\u3001\u6cbb\u7642\u5f8c\u3082\u809d\u767a\u304c\u3093\u3084\u809d\u6a5f\u80fd\u4f4e\u4e0b\u306e\u30ea\u30b9\u30af\u306f\u60a3\u8005\u80cc\u666f\u306b\u3088\u308a\u7570\u306a\u308a\u307e\u3059\u3002OLF\u306b\u304a\u3044\u3066\u3001DAA\u6cbb\u7642\u306b\u3088\u308aSVR\u3092\u9054\u6210\u3057\u305fC\u578b\u809d\u708e\u60a3\u8005\u3055\u3093\u306b\u304a\u3051\u308b\u3001\u521d\u767a\u809d\u767a\u764c\u7387\u306f4\u5e74\u30674.4%\u3067\u3042\u308a\u3001BMI\uff08\u2265 25 kg\/m2\uff09\u3001FIB-4 index\uff08\u2265 3.25\uff09\u3001SVR\u6642\u30a2\u30eb\u30d6\u30df\u30f3\u5024\uff08< 4.0 g\/dl\uff09\u3001SVR\u6642AFP\u5024\uff08\u2265 5 ng\/ml\uff09\u304c\u30ea\u30b9\u30af\u56e0\u5b50\u3067\u3057\u305f\u3002\u307e\u305f\u3001\u305d\u308c\u3089\u306e\u30ea\u30b9\u30af\u56e0\u5b50\u3092\u7528\u3044\u305f\u4e88\u6e2c\u30b9\u30b3\u30a2\u306b\u3088\u308a\u3001\u767a\u764c\u30ea\u30b9\u30af\u306e\u5c64\u5225\u5316\u304c\u53ef\u80fd\u3067\u3042\u3063\u305f\u3053\u3068\u3092\u660e\u3089\u304b\u306b\u3057\u307e\u3057\u305f1)\u3002\u307e\u305f\u3001B\u578b\u809d\u708e\u306b\u304a\u3044\u3066\u306f\u3001\u6838\u9178\u30a2\u30ca\u30ed\u30b0\u6cbb\u7642\u3067HBV-DNA\u304c\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb\u3067\u304d\u3066\u3044\u308b\u60a3\u8005\u3055\u3093\u306b\u304a\u3051\u308b\u521d\u767a\u809d\u767a\u764c\u7387\u306f7\u5e74\u306717.2%\u3067\u3042\u308a\u3001\u5e74\u9f62\uff08\u2265 55\u6b73\uff09\u3001\u809d\u786c\u5909\u3001\u6cbb\u7642\u958b\u59cb24\u9031\u6642\u306eAFP\u5024\uff08\u2265 10 ng\/ml\uff09\u304c\u30ea\u30b9\u30af\u56e0\u5b50\u3067\u3042\u308b\u3053\u3068\u3092\u660e\u3089\u304b\u306b\u3057\u307e\u3057\u305f2)\u3002\u5f97\u3089\u308c\u305f\u77e5\u898b\u3092\u57fa\u306b\u3001\u30cf\u30a4\u30ea\u30b9\u30af\u7fa4\u306e\u62bd\u51fa\u3001\u30b5\u30fc\u30d9\u30a4\u30e9\u30f3\u30b9\u9593\u9694\u3084\u4ecb\u5165\u30dd\u30a4\u30f3\u30c8\u306e\u6700\u9069\u5316\u306b\u7d50\u3073\u4ed8\u3051\u3001\u5b9f\u88c5\u53ef\u80fd\u306a\u5c64\u5225\u5316\u30e2\u30c7\u30eb\u3068\u3057\u3066\u767a\u4fe1\u3057\u307e\u3059\u3002\n\uff11\uff09Tahata Y, et al. Aliment Pharmacol Ther. 2021\n\uff12\uff09Yamada R, et al. J Gastroenterol. 2015<\/p>\n <\/div>\n\n

\n

\u809d\u7d30\u80de\u764c\u306b\u5bfe\u3059\u308b\u85ac\u7269\u6cbb\u7642\u52b9\u679c\u306eReal-World Evidence\u3068\u6cbb\u7642\u53cd\u5fdc\u4e88\u6e2c<\/h3>\n

\u809d\u7d30\u80de\u764c\u306e\u85ac\u7269\u7642\u6cd5\u306f\u591a\u69d8\u5316\u3057\u3066\u304a\u308a\u3001\u5b9f\u81e8\u5e8a\u3067\u306e\u6cbb\u7642\u52b9\u679c\u30fb\u6709\u5bb3\u4e8b\u8c61\u30fb\u809d\u6a5f\u80fd\u63a8\u79fb\u3092\u8e0f\u307e\u3048\u305f\u6700\u9069\u5316\u304c\u91cd\u8981\u3067\u3059\u3002OLF\u591a\u65bd\u8a2d\u30c7\u30fc\u30bf\u3067\u6cbb\u7642\u5225\u306e\u6709\u52b9\u6027\u30fb\u5b89\u5168\u6027\u30fb\u6cbb\u7642\u7d99\u7d9a\u6027\u3092\u6574\u7406\u3057\u3001\u594f\u52b9\u3084\u4e88\u5f8c\u306b\u95a2\u4e0e\u3059\u308b\u56e0\u5b50\u3092\u8a55\u4fa1\u3057\u3066\u3044\u307e\u3059\u3002\u30a2\u30c6\u30be\u30ea\u30ba\u30de\u30d6\u30fb\u30d9\u30d0\u30b7\u30ba\u30de\u30d6\u4f75\u7528\u7642\u6cd5\u3092\u53d7\u3051\u305f\u5207\u9664\u4e0d\u80fd\u809d\u7d30\u80de\u764c\u60a3\u8005\u3055\u3093\u306b\u304a\u3044\u3066\u3001\u8102\u8cea\u7570\u5e38\u75c7\u306e\u5408\u4f75\u7121\u3057\u3001\u809d\u5185\u816b\u760d\u500b\u6570\uff08\u2265 5\uff09\u3001\u8108\u7ba1\u6d78\u6f64\u6709\u308a\u3001AFP\u5024\uff08\u2265 400ng\/ml\uff09\u3001Child-Pugh score\uff08\u2265 6\uff09\u3001NLR\uff08\u2265 3.03\uff09\u304c\u4e88\u5f8c\u4e0d\u826f\u306b\u95a2\u4e0e\u3057\u3066\u3044\u308b\u3053\u3068\u3092\u5831\u544a\u3057\u307e\u3057\u305f\uff13\uff09\u3002\u307e\u305f\u3001\u30a2\u30c6\u30be\u30ea\u30ba\u30de\u30d6\u30fb\u30d9\u30d0\u30b7\u30ba\u30de\u30d6\u4f75\u7528\u7642\u6cd5\u3092\u53d7\u3051\u305f\u5207\u9664\u4e0d\u80fd\u809d\u7d30\u80de\u764c\u60a3\u8005\u3055\u3093\u306b\u304a\u3044\u3066\u3001\u6cbb\u7642\u958b\u59cb9\u9031\u4ee5\u5185\u306b\u9ad8\u8840\u5727\u306e\u6709\u5bb3\u4e8b\u8c61\u3092\u8a8d\u3081\u305f\u60a3\u8005\u3055\u3093\u306b\u304a\u3044\u3066\u3001\u4e88\u5f8c\u304c\u826f\u597d\u3067\u3042\u3063\u305f\u3053\u3068\u3092\u5831\u544a\u3057\u307e\u3057\u305f\uff14\uff09\u3002\u3055\u3089\u306b\u4fdd\u5b58\u8840\u6e05\u30fb\u809d\u7d44\u7e54\u3092\u7528\u3044\u3001\u53cd\u5fdc\u6027\/\u6bd2\u6027\/\u4e88\u5f8c\u3092\u5c64\u5225\u5316\u3057\u5f97\u308b\u30d0\u30a4\u30aa\u30de\u30fc\u30ab\u30fc\u5019\u88dc\u3092\u63a2\u7d22\u30fb\u691c\u8a3c\u3057\u3001\u6cbb\u7642\u9078\u629e\u306b\u8cc7\u3059\u308b\u6307\u6a19\u306e\u81e8\u5e8a\u5fdc\u7528\u53ef\u80fd\u6027\u3092\u691c\u8a0e\u3057\u307e\u3059\u3002\u6cbb\u7642\u30b7\u30fc\u30b1\u30f3\u30b9\u3084\u30d5\u30a9\u30ed\u30fc\u8a08\u753b\u306e\u6700\u9069\u5316\u306b\u3082\u3064\u306a\u3052\u307e\u3059\u3002\n\uff13\uff09Kai M, et al. PLoS One. 2024\n\uff14\uff09Maesaka K, et al. J Gastroenterol Hepatol. 2025<\/p>\n <\/div>\n\n

\n

\u8102\u80aa\u6027\u809d\u75be\u60a3\uff08MASLD\/MetALD\uff09\u30fb\u30a2\u30eb\u30b3\u30fc\u30eb\u95a2\u9023\u809d\u75be\u60a3\u306e\u9032\u5c55\u56e0\u5b50\u3068\u30ea\u30b9\u30af\u5c64\u5225\u5316<\/h3>\n

\u8102\u80aa\u6027\u809d\u75be\u60a3\u3084\u30a2\u30eb\u30b3\u30fc\u30eb\u95a2\u9023\u809d\u75be\u60a3\u306f\u60a3\u8005\u6570\u304c\u5897\u52a0\u3057\u3001\u7dda\u7dad\u5316\u9032\u5c55\u3084\u767a\u304c\u3093\u306b\u81f3\u308b\u7d4c\u8def\u306f\u591a\u69d8\u3067\u3059\u3002OLF\u3067\u306f\u3001\u8102\u80aa\u6027\u809d\u75be\u60a3\u60a3\u8005\u3055\u3093\u3092\u5bfe\u8c61\u3068\u3057\u305f\u524d\u5411\u304d\u89b3\u5bdf\u7814\u7a76\u3092\u884c\u3063\u3066\u304a\u308a\u3001\u4ee3\u8b1d\u7570\u5e38\u3001\u98f2\u9152\u91cf\u30fb\u98f2\u9152\u30d1\u30bf\u30fc\u30f3\u3001\u4f53\u91cd\u5909\u5316\u3001\u4f75\u5b58\u75be\u60a3\u306a\u3069\u65e5\u5e38\u8a3a\u7642\u60c5\u5831\u304b\u3089\u3001\u7dda\u7dad\u5316\u9032\u5c55\u30fb\u809d\u95a2\u9023\u30a4\u30d9\u30f3\u30c8\u30fb\u767a\u304c\u3093\u306e\u95a2\u9023\u56e0\u5b50\u3092\u8a55\u4fa1\u3057\u3001\u30ea\u30b9\u30af\u5c64\u5225\u5316\u30e2\u30c7\u30eb\u306e\u69cb\u7bc9\u3092\u9032\u3081\u3066\u3044\u307e\u3059\u3002\u4f75\u305b\u3066\u4fdd\u5b58\u8840\u6e05\u30fb\u4e00\u90e8\u809d\u7d44\u7e54\u3092\u7528\u3044\u3001\u9032\u5c55\u3092\u65e9\u671f\u306b\u6349\u3048\u308b\u6307\u6a19\u5019\u88dc\u3092\u63a2\u7d22\u30fb\u691c\u8a3c\u3057\u3001\u4eca\u5f8c\u627f\u8a8d\u304c\u671f\u5f85\u3055\u308c\u308b\u85ac\u7269\u7642\u6cd5\u306e\u6700\u9069\u5316\u306b\u8cc7\u3059\u308b\u8a55\u4fa1\u6cd5\u3092\u76ee\u6307\u3057\u307e\u3059\u3002\u3055\u3089\u306b\u3001\u7d4c\u6642\u7684\u306a\u691c\u67fb\u5024\u3084\u809d\u786c\u5ea6\u7b49\u306e\u63a8\u79fb\u3082\u53d6\u308a\u8fbc\u307f\u3001\u9032\u5c55\u9ad8\u30ea\u30b9\u30af\u7fa4\u306e\u540c\u5b9a\u3068\u30d5\u30a9\u30ed\u30fc\u9593\u9694\u306e\u63d0\u6848\u306b\u3064\u306a\u3052\u307e\u3059\u3002\u4fdd\u5b58\u8840\u6e05\u3067\u306f\u30e1\u30bf\u30dc\u30ed\u30fc\u30e0\u89e3\u6790\u7b49\u3082\u884c\u3044\u3001\u75c5\u614b\u3092\u53cd\u6620\u3059\u308b\u5019\u88dc\u30de\u30fc\u30ab\u30fc\u3092\u62bd\u51fa\u3057\u307e\u3059\u3002<\/p>\n <\/div>\n\n

\n

\u809d\u786c\u5909\u306b\u304a\u3051\u308b\u975e\u4ee3\u511f\u5316\u30a4\u30d9\u30f3\u30c8\u4e88\u6e2c\u3068\u4e88\u5f8c\u6539\u5584\u306b\u8cc7\u3059\u308b\u6307\u6a19\u63a2\u7d22<\/h3>\n

\u809d\u786c\u5909\u3067\u306f\u8179\u6c34\u30fb\u9759\u8108\u7624\u51fa\u8840\u30fb\u809d\u6027\u8133\u75c7\u306a\u3069\u306e\u975e\u4ee3\u511f\u5316\u30a4\u30d9\u30f3\u30c8\u304c\u4e88\u5f8c\u3092\u5927\u304d\u304f\u5de6\u53f3\u3057\u307e\u3059\u3002OLF\u3067\u306f\u3001\u809d\u786c\u5909\u60a3\u8005\u3055\u3093\u3092\u5bfe\u8c61\u3068\u3057\u305f\u524d\u5411\u304d\u89b3\u5bdf\u7814\u7a76\u3092\u884c\u3063\u3066\u304a\u308a\u3001\u809d\u4e88\u5099\u80fd\u6307\u6a19\u3001\u708e\u75c7\u30fb\u51dd\u56fa\u3001\u814e\u6a5f\u80fd\u3001\u5408\u4f75\u75c7\u6cbb\u7642\u306e\u5f71\u97ff\u3092\u7d71\u5408\u3057\u3066\u3001\u30a4\u30d9\u30f3\u30c8\u767a\u751f\u30fb\u518d\u5165\u9662\u30fb\u6b7b\u4ea1\u306b\u95a2\u308f\u308b\u56e0\u5b50\u3092\u8a55\u4fa1\u3057\u3001\u610f\u601d\u6c7a\u5b9a\u306b\u8cc7\u3059\u308b\u30ea\u30b9\u30af\u5c64\u5225\u5316\u3068\u30d5\u30a9\u30ed\u30fc\u6226\u7565\u306e\u6700\u9069\u5316\u3092\u884c\u3044\u307e\u3059\u3002\u3055\u3089\u306b\u4fdd\u5b58\u8840\u6e05\u30fb\u809d\u7d44\u7e54\u3092\u7528\u3044\u3001\u975e\u4ee3\u511f\u5316\u3084\u4e88\u5f8c\u60aa\u5316\u3092\u5148\u56de\u308a\u3057\u3066\u6349\u3048\u308b\u65b0\u898f\u30d0\u30a4\u30aa\u30de\u30fc\u30ab\u30fc\u5019\u88dc\u3092\u63a2\u7d22\u30fb\u691c\u8a3c\u3057\u3001\u5b9f\u88c5\u53ef\u80fd\u306a\u30ea\u30b9\u30af\u8a55\u4fa1\u3078\u3064\u306a\u3052\u307e\u3059\u3002<\/p>\n <\/div>\n\n

\n \"\u7814\u7a76\u5185\u5bb9\u56f3\"\n <\/div>\n <\/section>\n\n
\n

\u5c06\u6765\u5c55\u671b\uff1a\u300c\u8a3a\u7642\u3092\u652f\u3048\u308b\u300d\u304b\u3089\u300c\u8a3a\u7642\u3092\u5909\u3048\u308b\u300d\u3078\u2014\u56fd\u5185\u5916\u9023\u643a\u3068\u4ecb\u5165\u7814\u7a76\u306b\u3088\u308b\u65b0\u305f\u306a\u30a8\u30d3\u30c7\u30f3\u30b9\u5275\u51fa<\/h3>\n

\u3053\u308c\u307e\u3067OLF\u306f\u3001\u591a\u65bd\u8a2d\u524d\u5411\u304d\u89b3\u5bdf\u7814\u7a76\u3092\u57fa\u76e4\u306b\u3001\u65e5\u5e38\u8a3a\u7642\u3092\u652f\u3048\u308bReal-World Evidence\u3092\u7d99\u7d9a\u7684\u306b\u767a\u4fe1\u3057\u3066\u304d\u307e\u3057\u305f\u3002\u4eca\u5f8c\u306f\u3053\u306e\u5f37\u56fa\u306a\u57fa\u76e4\u3092\u3055\u3089\u306b\u767a\u5c55\u3055\u305b\u3001\u56fd\u5185\u5916\u306e\u5171\u540c\u7814\u7a76\u8005\u3068\u306e\u9023\u643a\u3092\u5f37\u5316\u3057\u3001\u56fd\u969b\u5171\u540c\u7814\u7a76\u3092\u901a\u3058\u305f\u666e\u904d\u6027\u306e\u9ad8\u3044\u77e5\u898b\u306e\u5275\u51fa\u3092\u76ee\u6307\u3057\u307e\u3059\u3002\u52a0\u3048\u3066\u3001\u89b3\u5bdf\u7814\u7a76\u3067\u5f97\u3089\u308c\u305f\u4eee\u8aac\u3092\u51fa\u767a\u70b9\u306b\u3001\u8a3a\u7642\u30d7\u30ed\u30bb\u30b9\u3084\u6cbb\u7642\u6226\u7565\u306e\u6700\u9069\u5316\u3092\u524d\u5411\u304d\u306b\u691c\u8a3c\u3059\u308b\u4ecb\u5165\u7814\u7a76\u3078\u5c55\u958b\u3057\u3001\u5b9f\u969b\u306b\u8a3a\u7642\u3092\u5909\u3048\u308b\u30a8\u30d3\u30c7\u30f3\u30b9\u306e\u5275\u51fa\u306b\u6311\u6226\u3057\u307e\u3059\u3002\u4fdd\u5b58\u8840\u6e05\u30fb\u809d\u7d44\u7e54\u3092\u6d3b\u7528\u3057\u305f\u30d0\u30a4\u30aa\u30de\u30fc\u30ab\u30fc\u7814\u7a76\u3082\u7d71\u5408\u3057\u3001\u5c64\u5225\u5316\u533b\u7642\u306e\u5b9f\u88c5\u3068\u60a3\u8005\u3055\u3093\u30fb\u793e\u4f1a\u3078\u306e\u9084\u5143\u3092\u52a0\u901f\u3055\u305b\u307e\u3059\u3002<\/p>\n <\/section>\n\n

\n

\u3010\u4e3b\u8981\u8ad6\u6587\u3011<\/h3>\n
    \n
  1. Tahata Y, Hikita H, Takaki A, Kurosaki M, Matsuura K, Yatsuhashi H, Kuroda H, Ueno Y, Maekawa S, Nakamura M, Sakamori R, Kodama T, Takehara T. Long-term changes in hepatic reserve and prognosis after direct-acting antiviral treatment in patients with hepatitis C virus-related decompensated cirrhosis: a five-year follow-up study of a Japanese phase 3 trial. J Gastroenterol. 2025 Oct 30. doi: 10.1007\/s00535-025-02312-1. Epub ahead of print. PMID: 41168423.<\/li>\n
  2. Maesaka K, Hikita H, Tahata Y, Nishioka C, Kai M, Shirai K, Murai K, Makino Y, Saito Y, Kodama T, Ohkawa K, Miyazaki M, Nozaki Y, Yakushijin T, Sakamori R, Tatsumi N, Matsumoto K, Ishida H, Iio S, Nawa T, Kakita N, Nakahara M, Hosui A, Yoshida Y, Usui T, Imanaka K, Doi Y, Sakakibara M, Takehara T. Comparative analysis of lenvatinib use after atezolizumab plus bevacizumab versus lenvatinib as first-line therapy in unresectable hepatocellular carcinoma. J Gastroenterol. 2026 Jan;61(1):68-77. doi: 10.1007\/s00535-025-02308-x. Epub 2025 Oct 25. PMID: 41139139.<\/li>\n
  3. Maesaka K, Hikita H, Kai M, Tahata Y, Shirai K, Doi A, Murai K, Saito Y, Yamada R, Kodama T, Ohkawa K, Miyazaki M, Ishida H, Matsumoto K, Nozaki Y, Yakushijin T, Sakamori R, Tatsumi N, Iio S, Nawa T, Kakita N, Nakahara M, Hosui A, Usui T, Imanaka K, Doi Y, Sakakibara M, Yoshida Y, Tatsumi T, Takehara T. Hypertension as an Adverse Event Potentially Impacting the Therapeutic Efficacy of Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma. J Gastroenterol Hepatol. 2025 Oct;40(10):2580-2590. doi: 10.1111\/jgh.70068. Epub 2025 Sep 9. PMID: 40922653; PMCID: PMC12511841.<\/li>\n
  4. Tahata Y, Hikita H, Mochida S, Enomoto N, Kawada N, Ido A, Miki D, Kurosaki M, Yoshiji H, Sakamori R, Kuroda H, Yatsuhashi H, Yamashita T, Hiasa Y, Kato N, Miyaaki H, Ueno Y, Itoh Y, Matsuura K, Takami T, Asahina Y, Suda G, Akuta N, Tateishi R, Nakamoto Y, Kakazu E, Terai S, Shimizu M, Miyazaki M, Nozaki Y, Sobue S, Yano H, Miyaki T, Moriuchi A, Hori T, Shirai K, Murai K, Saito Y, Kodama T, Tatsumi T, Yamada T, Takehara T. Factors involved in gastroesophageal varix-related events in patients with hepatitis C virus-related compensated and decompensated cirrhosis after direct-acting antiviral therapy. Hepatol Res. 2024 Oct 29. doi: 10.1111\/hepr.14131. Epub ahead of print. PMID: 39470448.<\/li>\n
  5. Kai M, Hikita H, Kazuki M, Tahata Y, Shinkai K, Doi A, Ohkawa K, Miyazaki M, Ishida H, Matsumoto K, Nozaki Y, Yakushijin T, Sakamori R, Kaneko A, Iio S, Nawa T, Kakita N, Morishita N, Hiramatsu N, Usui T, Imanaka K, Doi Y, Sakakibara M, Yoshida Y, Oze T, Kodama T, Tatsumi T, Takehara T. Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study. PLoS One. 2024 Jan 2;19(1):e0294590. doi: 10.1371\/journal.pone.0294590. PMID: 38165900; PMCID: PMC10760712.<\/li>\n
  6. Tahata Y, Hikita H, Mochida S, Enomoto N, Ido A, Kuroda H, Miki D, Kurosaki M, Hiasa Y, Sakamori R, Kawada N, Yamashita T, Suda G, Yatsuhashi H, Yoshiji H, Kato N, Takami T, Nakao K, Matsuura K, Asahina Y, Itoh Y, Tateishi R, Nakamoto Y, Kakazu E, Terai S, Shimizu M, Ueno Y, Akuta N, Miyazaki M, Nozaki Y, Kabayama M, Sobue S, Moriuchi A, Miyaki T, Kodama T, Tatsumi T, Yamada T, Takehara T. Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus. J Gastroenterol. 2023 Dec;58(12):1211-1221. doi: 10.1007\/s00535-023-02039-x. Epub 2023 Oct 13. PMID: 37831182; PMCID: PMC10657790.<\/li>\n
  7. Maesaka K, Sakamori R, Yamada R, Doi A, Tahata Y, Ohkawa K, Oshita M, Miyazaki M, Yakushijin T, Nozaki Y, Matsumoto K, Tanaka S, Kaneko A, Iio S, Nawa T, Yamada Y, Morishita N, Usui T, Hiramatsu N, Doi Y, Sakakibara M, Imanaka K, Yoshida Y, Kodama T, Hikita H, Tatsumi T, Takehara T. Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma. PLoS One. 2023 Feb 7;18(2):e0281459. doi: 10.1371\/journal.pone.0281459. PMID: 36749777; PMCID: PMC9904470.<\/li>\n
  8. Tahata Y, Sakamori R, Yamada R, Kodama T, Hikita H, Hagiwara H, Oshita M, Imai Y, Hiramatsu N, Mita E, Kaneko A, Miyazaki M, Ohkawa K, Hijioka T, Fukui H, Ito T, Yamamoto K, Doi Y, Yoshida Y, Yamada Y, Yakushijin T, Tatsumi T, Takehara T; Osaka Liver Forum. Improved Liver Function After Sustained Virologic Response Enhanced Prognosis in Hepatitis C with Compensated Advanced Liver Fibrosis. Dig Dis Sci. 2023 May;68(5):2115-2122. doi: 10.1007\/s10620-022-07629-y. Epub 2022 Dec 16. PMID: 36526814.<\/li>\n
  9. Tahata Y, Sakamori R, Maesaka K, Doi A, Yamada R, Kodama T, Hikita H, Miyazaki M, Nozaki Y, Kaneko A, Oshita M, Tanaka S, Imanaka K, Hiramatsu N, Morishita N, Ohkawa K, Yakushijin T, Sakakibara M, Iio S, Doi Y, Tatsumi T, Takehara T. Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosis. Hepatol Res. 2023 Apr;53(4):301-311. doi: 10.1111\/hepr.13868. Epub 2022 Dec 22. PMID: 36507871.<\/li>\n
  10. Tahata Y, Sakamori R, Yamada R, Kodama T, Hikita H, Nozaki Y, Oshita M, Hiramatsu N, Miyazaki M, Mita E, Yamamoto K, Ohkawa K, Kaneko A, Ito T, Doi Y, Yakushijin T, Hijioka T, Fukui H, Imanaka K, Yoshida Y, Yamada Y, Tatsumi T, Takehara T. Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis. Hepatol Res. 2022 Oct;52(10):824-832. doi: 10.1111\/hepr.13806. Epub 2022 Jul 8. PMID: 35749289.<\/li>\n
  11. Shinkai K, Sakamori R, Yamada R, Tahata Y, Nozaki Y, Matsumoto K, Tawara S, Fukuda K, Yoshida Y, Tanaka S, Ito T, Doi Y, Iio S, Sakakibara M, Nakanishi F, Kodama T, Hikita H, Tatsumi T, Takehara T. Prognostic impact of worsening of esophageal varices after balloon-occluded retrograde transvenous obliteration. J Gastroenterol Hepatol. 2022 Jun;37(6):1148-1155. doi: 10.1111\/jgh.15853. Epub 2022 Apr 26. PMID: 35430734.<\/li>\n
  12. Maesaka K, Sakamori R, Yamada R, Doi A, Tahata Y, Miyazaki M, Ohkawa K, Mita E, Iio S, Nozaki Y, Yakushijin T, Imai Y, Kodama T, Hikita H, Tatsumi T, Takehara T. Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma. Hepatol Res. 2022 Jul;52(7):630-640. doi: 10.1111\/hepr.13771. Epub 2022 Apr 25. PMID: 35417606.<\/li>\n
  13. Sakamori R, Yamada R, Tahata Y, Kodama T, Hikita H, Tatsumi T, Yamada T, Takehara T. The absence of warfarin treatment and situs inversus are associated with the occurrence of hepatocellular carcinoma after Fontan surgery. J Gastroenterol. 2022 Feb;57(2):111-119. doi: 10.1007\/s00535-021-01842-8. Epub 2022 Jan 22. PMID: 35064829.<\/li>\n
  14. Tahata Y, Hikita H, Mochida S, Enomoto N, Kawada N, Kurosaki M, Ido A, Miki D, Yoshiji H, Takikawa Y, Sakamori R, Hiasa Y, Nakao K, Kato N, Ueno Y, Yatsuhashi H, Itoh Y, Tateishi R, Suda G, Takami T, Nakamoto Y, Asahina Y, Matsuura K, Yamashita T, Kanto T, Akuta N, Terai S, Shimizu M, Sobue S, Miyaki T, Moriuchi A, Yamada R, Kodama T, Tatsumi T, Yamada T, Takehara T. Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis. J Gastroenterol. 2022 Feb;57(2):120-132. doi: 10.1007\/s00535-021-01845-5. Epub 2022 Jan 20. PMID: 35059853.<\/li>\n
  15. Maesaka K, Sakamori R, Yamada R, Tahata Y, Imai Y, Ohkawa K, Miyazaki M, Mita E, Ito T, Hagiwara H, Yakushijin T, Kodama T, Hikita H, Tatsumi T, Takehara T. Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy. Hepatol Res. 2022 Mar;52(3):298-307. doi: 10.1111\/hepr.13741. Epub 2021 Dec 28. Erratum in: Hepatol Res. 2022 Jul;52(7):659. doi: 10.1111\/hepr.13775. PMID: 34918428.<\/li>\n
  16. Tahata Y, Sakamori R, Yamada R, Kodama T, Hikita H, Hagiwara H, Imai Y, Hiramatsu N, Tamura S, Yamamoto K, Oshita M, Ohkawa K, Hijioka T, Fukui H, Ito T, Doi Y, Yamada Y, Yakushijin T, Yoshida Y, Tatsumi T, Takehara T; Osaka Liver Forum. Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct-acting anti-virals. Aliment Pharmacol Ther. 2021 Nov;54(10):1340-1349. doi: 10.1111\/apt.16632. Epub 2021 Oct 7. PMID: 34618934.<\/li>\n
  17. Maesaka K, Sakamori R, Yamada R, Tahata Y, Ohkawa K, Oshita M, Tamura S, Hagiwara H, Mita E, Yakushijin T, Inada M, Kodama T, Hikita H, Tatsumi T, Takehara T. Efficacy of Ramucirumab Versus Sorafenib as Subsequent Treatment for Hepatocellular Carcinoma. Anticancer Res. 2021 Apr;41(4):2187-2192. doi: 10.21873\/anticanres.14993. PMID: 33813432.<\/li>\n
  18. Maesaka K, Sakamori R, Yamada R, Tahata Y, Ohkawa K, Oshita M, Tamura S, Hagiwara H, Mita E, Yakushijin T, Inada M, Kodama T, Hikita H, Tatsumi T, Takehara T. Efficacy of Ramucirumab Versus Sorafenib as Subsequent Treatment for Hepatocellular Carcinoma. Anticancer Res. 2021 Apr;41(4):2187-2192. doi: 10.21873\/anticanres.14993. PMID: 33813432.<\/li>\n
  19. Maesaka K, Sakamori R, Yamada R, Tahata Y, Ohkawa K, Oshita M, Tamura S, Hagiwara H, Mita E, Yakushijin T, Inada M, Kodama T, Hikita H, Tatsumi T, Takehara T. Efficacy of Ramucirumab Versus Sorafenib as Subsequent Treatment for Hepatocellular Carcinoma. Anticancer Res. 2021 Apr;41(4):2187-2192. doi: 10.21873\/anticanres.14993. PMID: 33813432.<\/li>\n
  20. Tahata Y, Hikita H, Mochida S, Kawada N, Enomoto N, Ido A, Yoshiji H, Miki D, Hiasa Y, Takikawa Y, Sakamori R, Kurosaki M, Yatsuhashi H, Tateishi R, Ueno Y, Itoh Y, Yamashita T, Kanto T, Suda G, Nakamoto Y, Kato N, Asahina Y, Matsuura K, Terai S, Nakao K, Shimizu M, Takami T, Akuta N, Yamada R, Kodama T, Tatsumi T, Yamada T, Takehara T. Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study. J Gastroenterol. 2021 Jan;56(1):67-77. doi: 10.1007\/s00535-020-01733-4. Epub 2020 Oct 1. PMID: 33001338.<\/li>\n <\/ol>\n <\/section>\n\n <\/div>\n<\/main>\n","protected":false},"excerpt":{"rendered":"

    \u809d\u75be\u60a3\u81e8\u5e8a\u7814\u7a76\u30b0\u30eb\u30fc\u30d7 \u30b0\u30eb\u30fc\u30d7\u30ea\u30fc\u30c0\u30fc\uff1a\u7530\u7551\u512a\u8cb4 \u30b3\u30f3\u30bb\u30d7\u30c8\uff1aReal-World Evidence \u2500 \u65e5\u5e38\u8a3a\u7642\u306e\u7591\u554f\u3092\u591a\u65bd\u8a2d\u30c7\u30fc\u30bf\u3067\u691c\u8a3c\u3057\u3001\u8a3a\u7642\u3078\u9084\u5143\u3059\u308b \u79c1\u305f\u3061\u306f\u3001\u65e5\u5e38\u8a3a\u7642\u3067\u751f\u307e\u308c\u308b\u809d\u75be\u60a3\u306e clinical q […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":124,"menu_order":0,"comment_status":"open","ping_status":"open","template":"","meta":{"footnotes":""},"folder":[14],"class_list":["post-398","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gh\/wp-json\/wp\/v2\/pages\/398","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gh\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gh\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gh\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gh\/wp-json\/wp\/v2\/comments?post=398"}],"version-history":[{"count":1,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gh\/wp-json\/wp\/v2\/pages\/398\/revisions"}],"predecessor-version":[{"id":406,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gh\/wp-json\/wp\/v2\/pages\/398\/revisions\/406"}],"up":[{"embeddable":true,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gh\/wp-json\/wp\/v2\/pages\/124"}],"wp:attachment":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gh\/wp-json\/wp\/v2\/media?parent=398"}],"wp:term":[{"taxonomy":"folder","embeddable":true,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gh\/wp-json\/wp\/v2\/folder?post=398"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}